These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27046463)

  • 1. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
    Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
    Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
    Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
    Elife; 2016 Nov; 5():. PubMed ID: 27879203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
    Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
    Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
    Grundler R; Miething C; Thiede C; Peschel C; Duyster J
    Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.
    Nabinger SC; Li XJ; Ramdas B; He Y; Zhang X; Zeng L; Richine B; Bowling JD; Fukuda S; Goenka S; Liu Z; Feng GS; Yu M; Sandusky GE; Boswell HS; Zhang ZY; Kapur R; Chan RJ
    Leukemia; 2013 Feb; 27(2):398-408. PubMed ID: 23103841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
    Gerloff D; Grundler R; Wurm AA; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Madan V; Müller-Tidow C; Duyster J; Tenen DG; Niederwieser D; Behre G
    Leukemia; 2015 Mar; 29(3):535-47. PubMed ID: 25092144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
    Leischner H; Albers C; Grundler R; Razumovskaya E; Spiekermann K; Bohlander S; Rönnstrand L; Götze K; Peschel C; Duyster J
    Blood; 2012 Apr; 119(17):4026-33. PubMed ID: 22411868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.
    Nakajima H; Shibata F; Kumagai H; Shimoda K; Kitamura T
    Int J Hematol; 2006 Jul; 84(1):54-9. PubMed ID: 16867903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
    Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
    Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
    Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations.
    Seedhouse CH; Pallis M; Grundy M; Shang S; Russell NH
    Br J Haematol; 2009 Dec; 147(5):653-61. PubMed ID: 19775300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
    Chougule RA; Kazi JU; Rönnstrand L
    Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia.
    Rudorf A; Müller TA; Klingeberg C; Kreutmair S; Poggio T; Gorantla SP; Rückert T; Schmitt-Graeff A; Gengenbacher A; Paschka P; Baldus C; Zeiser R; Vassiliou GS; Bradley A; Duyster J; Illert AL
    Blood; 2019 Jul; 134(4):383-388. PubMed ID: 31186273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.
    Li L; Piloto O; Nguyen HB; Greenberg K; Takamiya K; Racke F; Huso D; Small D
    Blood; 2008 Apr; 111(7):3849-58. PubMed ID: 18245664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics.
    Kellner F; Keil A; Schindler K; Tschongov T; Hünninger K; Loercher H; Rhein P; Böhmer SA; Böhmer FD; Müller JP
    J Cell Mol Med; 2020 Apr; 24(8):4668-4676. PubMed ID: 32155324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
    Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
    J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.